2022
State insurance mandates for in vitro fertilization are not associated with improving racial and ethnic disparities in utilization and treatment outcomes
Correia K, Kraschel K, Seifer D. State insurance mandates for in vitro fertilization are not associated with improving racial and ethnic disparities in utilization and treatment outcomes. American Journal Of Obstetrics And Gynecology 2022, 228: 313.e1-313.e8. PMID: 36356698, DOI: 10.1016/j.ajog.2022.10.043.Peer-Reviewed Original ResearchConceptsNon-Hispanic white womenClinical outcomesEthnic disparitiesFertilization cyclesFertility careAssisted Reproductive Technology Clinical Outcomes Reporting SystemBlack/African American womenWhite womenSingle stimulation cycleInsurance mandatesReproductive-aged womenRecent study yearsLack of insuranceAfrican American womenAutologous cyclesLiveborn neonatesCohort studyPrimary outcomeState insurance mandatesState health insurance mandatesStimulation cyclesTreatment outcomesWomenHealth insurance mandatesOutcomes
2018
Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions
Zagadailov P, Hsu A, Stern JE, Seifer DB. Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions. Obstetrics And Gynecology 2018, 132: 310-320. PMID: 29995722, DOI: 10.1097/aog.0000000000002730.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsCohort StudiesFemaleFertilization in VitroHumansInfertility, FemaleInfertility, MaleLive BirthMalePregnancyPregnancy RateRetrospective StudiesSperm Injections, IntracytoplasmicTreatment OutcomeUnited StatesUnited States Dept. of Health and Human ServicesYoung AdultConceptsLive birth rateUse of ICSIICSI rateICSI utilizationBirth rateRetrospective cohort studyMale factor infertilityHuman Services (HHS) regionsIntracytoplasmic sperm injectionYears of agePreimplantation genetic testingMale factor diagnosisDepartment of HealthNondonor cyclesCohort studyFertilization cyclesFactor infertilityMale factorSperm injectionMedical indicationsMagnitude of increaseClinicGenetic testingDisease controlICSI
2014
Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reproductive Biology And Endocrinology 2014, 12: 82. PMID: 25141961, PMCID: PMC4150963, DOI: 10.1186/1477-7827-12-82.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesDown-RegulationFamily CharacteristicsFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleInfertility, MaleMaleNew York CityOocyte RetrievalOvarian ReserveOvulation InductionPlacenta Growth FactorPolycystic Ovary SyndromePregnancyPregnancy ProteinsPregnancy RateProspective StudiesUp-RegulationVascular Endothelial Growth Factor Receptor-1ConceptsNon-PCOS controlsPCOS womenOvarian stimulationSFlt-1 levelsAnti-Mullerian hormonePlacental growth factorVascular endothelial growth factorFollicular fluidOvarian syndromeSFlt-1Growth factorSoluble receptor sFlt-1BackgroundPolycystic ovarian syndromeControlled ovarian stimulationPlGF/sFltDay of hCGProspective cohort studyPolycystic ovarian syndromeNumber of oocytesEndothelial growth factorVEGF family membersCohort studyOocyte retrievalPlGF levelsVascular changesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2012
Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study
Merhi ZO, Seifer DB, Weedon J, Adeyemi O, Holman S, Anastos K, Golub ET, Young M, Karim R, Greenblatt R, Minkoff H. Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study. Fertility And Sterility 2012, 98: 228-234. PMID: 22494925, PMCID: PMC3389125, DOI: 10.1016/j.fertnstert.2012.03.029.Peer-Reviewed Original ResearchConceptsWomen's Interagency HIV StudySerum antimüllerian hormoneAntimüllerian hormoneInsulin levelsHIV StudyAged womenGroup 2Group 1Group 3Serum antimüllerian hormone levelsVitamin D correlateAntimüllerian hormone levelsGlomerular filtration rateLow ovarian reserveRegular menstrual cyclesBody mass indexCross-sectional studyIllicit drug usePremenopausal womenCreatinine levelsOvarian reserveHIV statusMass indexD levelsFiltration rate
2010
Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States
Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertility And Sterility 2010, 95: 747-750. PMID: 21074758, DOI: 10.1016/j.fertnstert.2010.10.011.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormone valuesAMH valuesHormone valuesAge 35Mean AMH valueSerum AMH valuesAverage yearly decreaseYears of ageU.S. fertility clinicsSpecific medianAMH levelsClinical reference laboratoryRetrospective studyFertility centerReproductive ageMAIN OUTCOMEAge 40Rate of declineFertility clinicsReference laboratoryWomenAgeReproductive optionsYearly decreaseSD values
2009
Trends of racial disparities in assisted reproductive technology outcomes in black women compared with white women: Society for Assisted Reproductive Technology 1999 and 2000 vs. 2004–2006
Seifer DB, Zackula R, Grainger DA, Report S. Trends of racial disparities in assisted reproductive technology outcomes in black women compared with white women: Society for Assisted Reproductive Technology 1999 and 2000 vs. 2004–2006. Fertility And Sterility 2009, 93: 626-635. PMID: 19368916, DOI: 10.1016/j.fertnstert.2009.02.084.Peer-Reviewed Original ResearchConceptsWhite womenCycles of IVFPoor prognostic factorReproductive technology outcomesNon-Hispanic womenBlack womenTubal factorIVF cyclesOvulation disordersCohort studyOvarian reserveIVF outcomesPrognostic factorsUterine factorsReporting of raceMale factorLive birthsMAIN OUTCOMEART outcomesMember clinicsOlder ageRacial disparitiesWomenFresh embryosReproductive technologies
2008
Plasma brain-derived neurotrophic factor in women after bariatric surgery: a pilot study
Merhi ZO, Minkoff H, Lambert-Messerlian GM, Macura J, Feldman J, Seifer DB. Plasma brain-derived neurotrophic factor in women after bariatric surgery: a pilot study. Fertility And Sterility 2008, 91: 1544-1548. PMID: 18950757, DOI: 10.1016/j.fertnstert.2008.09.032.Peer-Reviewed Original ResearchVariations in serum müllerian inhibiting substance between white, black, and Hispanic women
Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, Cohen MH, Karim R, Young MA, Minkoff H, Greenblatt RM. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertility And Sterility 2008, 92: 1674-1678. PMID: 18930217, PMCID: PMC3037722, DOI: 10.1016/j.fertnstert.2008.08.110.Peer-Reviewed Original ResearchConceptsBody mass indexHispanic womenHIV statusMass indexMulticenter prospective cohort studyWomen's Interagency HIV StudySerum MIS levelsProspective cohort studyTime pointsCohort studyDifferent time pointsMIS levelsAge-related declineHIV StudyDifferent time coursesMAIN OUTCOMESubstance levelsSerum MISWhite womenSerum samplesDifferent racial groupsWomenIndependent effectsLongitudinal studySmoking
2007
Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women
Seifer DB, Golub ET, Lambert-Messerlian G, Springer G, Holman S, Moxley M, Cejtin H, Nathwani N, Anastos K, Minkoff H, Greenblatt RM. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertility And Sterility 2007, 88: 1645-1652. PMID: 17418155, PMCID: PMC2682326, DOI: 10.1016/j.fertnstert.2007.01.122.Peer-Reviewed Original ResearchConceptsWomen's Interagency HIV StudyEarly follicular phaseOvarian reserveInhibin BHIV infectionMIS levelsFollicular phaseHIV StudyLower inhibin B levelsReproductive agingSerum samplesHIV infection influencesInhibin B levelsMulticenter prospective studyCross-sectional studyMenstrual cycle phaseCycle phaseUninfected womenCohort studyFSH levelsMenstrual bleedingNegative womenHIV serostatusSerum markersProspective study
2000
Progesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies
PHIPPS M, HOGAN J, PEIPERT J, LAMBERT-MESSERLIAN G, CANICK J, SEIFER D. Progesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies. Obstetrics And Gynecology 2000, 95: 227-231. DOI: 10.1097/00006250-200002000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkersProgesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies.
Phipps M, Hogan J, Peipert J, Lambert-Messerlian G, Canick J, Seifer D. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstetrics And Gynecology 2000, 95: 227-31. PMID: 10674584, DOI: 10.1016/s0029-7844(99)00480-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkers
1997
Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction
Friedman C, Danforth D, Herbosa-Encarnacion C, Arbogast L, Alak B, Seifer D. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertility And Sterility 1997, 68: 607-612. PMID: 9341598, DOI: 10.1016/s0015-0282(97)00278-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingCobaltCohort StudiesCorpus LuteumEndothelial Growth FactorsFemaleFollicular FluidGranulosa CellsHumansHypoxiaLymphokinesMaternal AgeMiddle AgedOsmolar ConcentrationOvulation InductionPregnancyPregnancy, High-RiskRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsAdvanced reproductive ageVascular endothelial growth factor/vascular permeability factorVascular permeability factorReproductive ageFollicular fluidFactor concentrationsPermeability factorFollicular fluid vascular endothelial growth factor concentrationsGranulosa cellsVascular endothelial growth factor concentrationsYoung womenRetrospective cohort studyReproductive-age womenUniversity Teaching HospitalPg/mLGrowth factor concentrationsCohort studyIVF-ETOvulation inductionHCG administrationAge womenCobalt chlorideTeaching hospitalMAIN OUTCOMEFollicular aspiration
1993
Comparison of persistent ectopic pregnancy after laparoscopic salpingostomy versus salpingostomy at laparotomy for ectopic pregnancy.
Seifer DB, Gutmann JN, Grant WD, Kamps CA, DeCherney AH. Comparison of persistent ectopic pregnancy after laparoscopic salpingostomy versus salpingostomy at laparotomy for ectopic pregnancy. Obstetrics And Gynecology 1993, 81: 378-82. PMID: 8437790.Peer-Reviewed Original ResearchConceptsPersistent ectopic pregnancyAmpullary ectopic pregnancyEctopic pregnancyLaparoscopic salpingostomyYale-New Haven HospitalConfidence interval (CI) 1.1Days of amenorrheaStepwise logistic regressionEctopic sizeLaparoscopic approachMedical recordsOdds ratioLaparotomySalpingostomyPregnancyLogistic regressionWomenAmenorrheaPatientsHospital
1992
Baseline ovarian cysts do not affect clinical response to controlled ovarian hyperstimulation for in vitro fertilization**Presented at the 47th Annual Meeting of The American Fertility Society, Orlando, Florida, October 21 to 24, 1991.
Penzias A, Jones E, Seifer D, Grifo J, Thatcher S, DeCherney A. Baseline ovarian cysts do not affect clinical response to controlled ovarian hyperstimulation for in vitro fertilization**Presented at the 47th Annual Meeting of The American Fertility Society, Orlando, Florida, October 21 to 24, 1991. Fertility And Sterility 1992, 57: 1017-1021. PMID: 1572468, DOI: 10.1016/s0015-0282(16)55019-5.Peer-Reviewed Original ResearchConceptsBaseline ovarian cystsNumber of folliclesOvarian cystsOvarian hyperstimulationIVF cyclesClinical responseStimulation regimenBaseline E2 levelBaseline serum estradiolCycle cancellation ratePeak serum E2Vitro Fertilization ProgramAmerican Fertility SocietyNumber of oocytesSerum E2Serum estradiolNumber of cystsCycle outcomeE2 levelsCyst sizeFertility SocietySuch cystsCancellation rateYale University SchoolOwn control